| Literature DB >> 22938590 |
Bo Ji1, Ben Ernest, Jessica R Gooding, Suchita Das, Arnold M Saxton, Jean Simon, Joelle Dupont, Sonia Métayer-Coustard, Shawn R Campagna, Brynn H Voy.
Abstract
BACKGROUND: Domestic broiler chickens rapidly accumulate adipose tissue due to intensive genetic selection for rapid growth and are naturally hyperglycemic and insulin resistant, making them an attractive addition to the suite of rodent models used for studies of obesity and type 2 diabetes in humans. Furthermore, chicken adipose tissue is considered as poorly sensitive to insulin and lipolysis is under glucagon control. Excessive fat accumulation is also an economic and environmental concern for the broiler industry due to the loss of feed efficiency and excessive nitrogen wasting, as well as a negative trait for consumers who are increasingly conscious of dietary fat intake. Understanding the control of avian adipose tissue metabolism would both enhance the utility of chicken as a model organism for human obesity and insulin resistance and highlight new approaches to reduce fat deposition in commercial chickens.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22938590 PMCID: PMC3503602 DOI: 10.1186/1471-2164-13-441
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Venn diagram of overlapping and unique effects of fasting and insulin neutralization on gene expression. (A) A total of 2016 unique genes were differentially expressed (FDR adjusted p-value <0.05) between one or more pairwise treatment comparisons; (B) A total of 1401 genes with absolute fold change ≥1.5 among the differentially expressed genes.
Fold change verification of gene expression by RT-PCR
| FBXO8 | F-box protein 8 | 4.16*** | 2.09** | −1.99*** | 2.59*** | 2.76*** | 1.06 |
| DUSP5 | Dual specificity phosphatase 5 | 9.43*** | 1.05 | −8.98*** | 8.13*** | 1.69*** | −4.82*** |
| BNIP3 | BCL2/adenovirus E1B 19 kDa interacting protein 3 | 2.98*** | 1.53 | −1.95** | 3.45*** | 2.26*** | −1.52* |
| PBX3 | Pre-B-cell leukemia homeobox 3 | −1.62*** | 1.07 | 1.75*** | −1.22 | 1.83*** | 2.22*** |
| IL10RB | Interleukin 10 receptor, beta | 1.74*** | 1.02 | −1.71** | 1.76*** | 1.42* | −1.24 |
| EGR1 | Early growth response 1 | 2.43* | −1.58 | −3.86** | 2.58*** | −1.36 | −3.52*** |
| NAB1 | NGFI-A binding protein 1 (EGR1 binding protein 1) | 2.43*** | 1.06 | −2.29*** | 1.67** | 1.52** | −1.10 |
| PDK4 | Pyruvate dehydrogenase kinase, isozyme 4 | 17.28*** | 7.06** | −2.45** | 18.33*** | 4.01*** | −4.57*** |
| CTSL2 | Cathepsin L2 | 2.09*** | 1.55* | −1.35* | 2.96*** | 2.053*** | −1.44 |
| AGTR1 | Angiotensin II receptor, type 1 | 4.15 *** | 2.05* | −2.02** | 3.52** | 1.72* | −2.05* |
| SESN1 | Sestrin 1 | 1.86** | 1.125 | −1.65 | 1.58* | 1.47* | 1.07 |
FDR p-value: * p < 0.05, ** p < 0.005, *** p < 0.0005.
Figure 2Cluster analysis of differentially expressed genes. The 2016 genes differentially expressed in one or both treatment groups vs. fed controls were subjected to hierarchical clustering to visualize similarities and differences between treatment groups. (A). Hierarchical cluster analysis of the 2016 genes (FDR adjusted p-value <0.05) that were differentially expressed between insulin-neutralized vs. fed and/or fasted vs. fed states. (B) Seven clusters (numbers) representing the most distinct effects of treatment were selected to further analyze expression profiles across treatments. Sample ID number on the X-axis corresponds to treatment group: sample 1–5, fasted; 6–10, insulin neutralized; 11–15,fed control. Y-axis represents relative gene expression value.
Gene ontology (GO) and KEGG annotation for representative clusters of differentially expressed genes
| 1, 3 and 4 (731 genes) | GO | Positive regulation of protein metabolic process | 6.0 E-3 |
| Negative regulation of cellular macromolecule biosynthetic process | 7.3 E-3 | ||
| | Triglyceride metabolic process | 1.0 E-2 | |
| | Negative regulation of gene expression | 1.0 E-2 | |
| | Proteolysis involved in cellular protein catabolic process | 1.0 E-2 | |
| | Negative regulation of kinase activity | 1.5 E-2 | |
| | Regulation of transcription, DNA-dependent | 2.1 E-2 | |
| | Protein phosphorylation | 3.3 E-2 | |
| | Antigen receptor-mediated signaling pathway | 3.3 E-2 | |
| | Regulation of phosphate metabolic process | 3.4 E-2 | |
| | Regulation of kinase activity | 3.4 E-2 | |
| | Regulation of I-kappaB kinase/NF-kappaB cascade | 3.5 E-2 | |
| KEGG | Ubiquitin mediated proteolysis | 1.0 E-2 | |
| | Sphingolipid metabolism | 1.8 E-2 | |
| | PPAR signaling pathway | 2.4 E-2 | |
| | Fatty acid metabolism | 4.6 E-2 | |
| | Peroxisome | 5.0 E-2 | |
| 2 (557 genes) | GO | Monosaccharide catabolic process | 2.5 E-2 |
| DNA dependent DNA replication | 3.6 E-3 | ||
| | Hexose metabolic process | 1.1 E-2 | |
| | Glucose metabolic process | 1.4 E-2 | |
| | | Regulation of cell shape | 1.5 E-2 |
| | | DNA replication | 1.5 E-2 |
| | | Nucleoside triphosphate metabolic | 2.3 E-2 |
| | KEGG | Glycolysis / Gluconeogenesis | 4.9 E-4 |
| | | Citrate cycle (TCA cycle) | 8.9 E-4 |
| 6 (402 genes) | KEGG | Steroid biosynthesis | 4.4 E-3 |
| | Glyoxylate and dicarboxylate metabolism | 1.2 E-2 | |
| | | Pyruvate metabolism | 3.3 E-2 |
| 5 and 7 (250 genes) | GO | Enzyme linked receptor protein signaling pathway | 9.7 E-3 |
| Regulation of cellular protein metabolic process | 3.1 E-2 | ||
| | | Negative regulation of macromolecule metabolic process | 3.5 E-2 |
| | | Transmembrane receptor protein serine/threonine kinase signaling pathway | 3.6 E-2 |
| | | Negative regulation of protein metabolic process | 3.7 E-2 |
| | | Positive regulation of cellular metabolic process | 4.4 E-2 |
| | KEGG | PPAR signaling pathway | 1.0 E-4 |
| | | Glycerolipid metabolism | 1.8 E-2 |
| MAPK signaling pathway | 4.6 E-2 |
Shared effects of fasting and insulin-neutralization on differential gene expression
| PDK4 | pyruvate dehydrogenase kinase, isozyme 4 | 7.06 | 17.28 |
| AOX1 | aldehyde oxidase 1 | 2.94 | 6.66 |
| PLEKHH2 | pleckstrin homology domain containing, family H (with MyTH4 domain) member 2 | 2.41 | 2.77 |
| FBXO8 | F-box protein 8 | 2.09 | 4.15 |
| AGTR1 | angiotensin II receptor, type 1 | 2.04 | 4.15 |
| PCMTD1 | protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 | 1.99 | 2.25 |
| PSME4 | proteasome (prosome, macropain) activator subunit 4 | 1.97 | 3.86 |
| ICA1 | islet cell autoantigen 1, 69 kDa | 1.85 | 2.8 |
| IP6K2 | inositol hexakisphosphate kinase 2 | 1.77 | 2.75 |
| UHRF2 | ubiquitin-like, containing PHD and RING finger domains, 2 | 1.72 | 1.89 |
| ACBD5 | acyl-Coenzyme A binding domain containing 5 | 1.72 | 2.51 |
| LOC417776 | similar to hypothetical protein | 1.62 | 1.84 |
| CTSL2 | cathepsin L2 | 1.54 | 2.09 |
| ZNF217 | zinc finger protein 217 | 1.54 | 2.6 |
| IFNAR1 | Interferon (alpha, beta and omega) receptor 1 | 1.52 | 3.47 |
| DGAT2 | diacylglycerol O-acyltransferase homolog 2 (mouse) | 6.1 | 10.5 |
| EEPD1 | endonuclease/exonuclease/phosphatase family domain containing 1 | 2.4 | 2.17 |
| ANKRD9 | ankyrin repeat domain 9 | 2.19 | 1.98 |
| DLST | dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex | 1.95 | 1.76 |
| PTP4A3 | protein tyrosine phosphatase type IVA, member 3 | 1.8 | 2.3 |
| HSPA5 | heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) | 1.76 | 1.74 |
| NOLA2 | nucleolar protein family A, member 2 (H/ACA small nucleolar RNPs) | 1.73 | 1.57 |
| MST1R | macrophage stimulating 1 receptor (c-met-related tyrosine kinase) | 1.71 | 2.2 |
| GRAMD2 | GRAM domain containing 2 | 1.69 | 2.37 |
| DHDDS | dehydrodolichyl diphosphate synthase | 1.63 | 1.58 |
| DYNLL2 | dynein, light chain, LC8-type 2 | 1.6 | 2.52 |
| CDT1 | chromatin licensing and DNA replication factor 1 | 1.57 | 1.51 |
| FAHD1 | fumarylacetoacetate hydrolase domain containing 1 | 1.56 | 1.61 |
| DOT1L | DOT1-like, histone H3 methyltransferase (S. cerevisiae) | 1.56 | 1.82 |
| BTBD11 | BTB (POZ) domain containing 11 | 1.55 | 1.71 |
FDR p-value <0.05.
Unique effects of insulin neutralization on differential gene expression
| | | ||||
|---|---|---|---|---|---|
| GCG | Glucagon | 2.91 | LOC425670 | glucagon receptor precursor | 2.77 |
| TCP11L2 | t-complex 11 (mouse)-like 2 | 2.08 | BAK1 | BCL2-antagonist/killer 1 | 1.83 |
| LOC416916 | hypothetical LOC416916 | 1.98 | CCT3 | chaperonin containing TCP1, subunit 3 (gamma) | 1.62 |
| MAGI1 | membrane associated guanylate kinase, WW and PDZ domain containing 1 | 1.84 | SETD7 | SET domain containing (lysine methyltransferase) 7 | 1.62 |
| SEPT10 | septin 10 | 1.79 | ST13 | suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein) | 1.62 |
| LSM14A | LSM14A, SCD6 homolog A (S. cerevisiae); similar to LSM14 homolog A (SCD6, S. cerevisiae) | 1.71 | AHSA1 | AHA1, activator of heat shock 90 kDa protein ATPase homolog 1 (yeast) | 1.62 |
| | | | TOE1 | target of EGR1, member 1 (nuclear) | 1.59 |
| AZIN1 | antizyme inhibitor 1 | 1.56 | |||
FDR p-value <0.05.
Fold change of fasting and insulin neutralization on adipose tissue metabolites
| adenosine | 0.57 | 1.21 | 2.12* |
| alanine | 0.66 | 1.57 | 2.38*** |
| arginine | 0.75 | 1.34 | 1.78** |
| asparagine | 0.47*** | 1.00 | 2.15*** |
| D-glucono-1,5-lactone-6-phosphate | 0.86 | 0.75* | 0.87 |
| glutamine | 0.48*** | 1.64* | 3.43**** |
| glycerol-3-phosphate | 0.82 | 0.72* | 0.87 |
| histidine | 0.64 | 1.38 | 2.17*** |
| hypoxanthine | 1.31 | 0.80 | 0.61** |
| N-acetyl-glutamate | 0.64 | 1.34 | 2.09* |
| N-acetyl-L-serine | 0.23** | 1.70 | 7.30*** |
| ornithine | 0.77 | 1.59 | 2.05* |
| proline | 0.63 | 1.50 | 2.39*** |
| serine | 0.67 | 1.61 | 2.39*** |
| threonine | 0.77 | 1.38 | 1.80** |
| tyrosine | 0.74 | 1.30 | 1.76** |
| a hexose-phosphate | 1.05 | 1.32** | 1.26* |
* p < 0.10, ** p < 0.05, *** p < 0.01, **** p < 0.001.
Figure 3KEGG pathway analysis of genes differentially expressed in fasting vs. fed. Genes differentially expressed in fasting vs. fed were matched to KEGG pathway membership using ClueGO. The percentage and #genes/term indicates the percentage and number of the genes in the pathway that are contained in the set of genes altered by fasting. · p < 0.1 * p < 0.05 **, p < 0.01, based on Benjamini-corrected p-value.
Figure 4Heat map of metabolites. The median value of each metabolite in each treatment group was used to calculate fold-change of fasted vs. fed, insulin-neutralized (insneut) vs. fed, and insulin-neutralized vs. fasted, and then values were subjected to hierarchical clustering.